PureTech Health unveiled positive Phase 2b data on Monday for its idiopathic pulmonary fibrosis drug, which showed it can ...
Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review
Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with ...
FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...
Organon won a label expansion for the steroid-free topical cream it picked up from its October acquisition of Dermavant.
The European Medicines Agency’s human medicines committee (CHMP) handed down 17 recommendations for drug approvals on Friday ...
Bicycle Therapeutics reports mixed data for zelenectide pevedotin in cancer trials, with 60% response rate in urothelial ...
Endpoints Weekly covers ASH conference highlights, FDA discussions on Moderna's RSV vaccine safety, Biosecure Act exclusion, and industry updates from biotech leaders.
The FDA is pushing back against claims that its safety restrictions for the abortion pill mifepristone are “onerous and ...
Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron
The billion-dollar AI-focused startup Xaira Therapeutics deepened its C-suite this week, hiring former Roche executive Paulo ...
Boundless Bio is trimming its oncology pipeline in the wake of disappointing cancer data and switching up its leadership just ...
Cases of severe RSV in two Moderna vaccine candidates' trials raise questions about future
Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children ...
In an attempt to continue its I&I dominance beyond Humira, Skyrizi and Rinvoq, AbbVie is buying up another small autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback